Septerna (SEPN) Competitors $6.29 +0.15 (+2.44%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$6.30 +0.01 (+0.24%) As of 03/27/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SEPN vs. AUPH, ADPT, SYRE, SNDX, SPRY, NRIX, ELVN, NTLA, BGM, and RCUSShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Aurinia Pharmaceuticals (AUPH), Adaptive Biotechnologies (ADPT), Spyre Therapeutics (SYRE), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Aurinia Pharmaceuticals Adaptive Biotechnologies Spyre Therapeutics Syndax Pharmaceuticals ARS Pharmaceuticals Nurix Therapeutics Enliven Therapeutics Intellia Therapeutics Qilian International Holding Group Arcus Biosciences Septerna (NASDAQ:SEPN) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community favor SEPN or AUPH? Aurinia Pharmaceuticals received 572 more outperform votes than Septerna when rated by MarketBeat users. However, 83.33% of users gave Septerna an outperform vote while only 73.41% of users gave Aurinia Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSepternaOutperform Votes583.33% Underperform Votes116.67%Aurinia PharmaceuticalsOutperform Votes57773.41% Underperform Votes20926.59% Does the media prefer SEPN or AUPH? In the previous week, Septerna had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 7 mentions for Septerna and 3 mentions for Aurinia Pharmaceuticals. Septerna's average media sentiment score of 1.89 beat Aurinia Pharmaceuticals' score of 1.62 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SEPN or AUPH more profitable? Septerna has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Septerna's return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Aurinia Pharmaceuticals -10.23%-4.41%-3.07% Which has better earnings & valuation, SEPN or AUPH? Septerna has higher earnings, but lower revenue than Aurinia Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$981K284.70N/AN/AN/AAurinia Pharmaceuticals$235.13M4.94-$78.02M$0.05169.20 Do insiders and institutionals hold more shares of SEPN or AUPH? 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer SEPN or AUPH? Septerna presently has a consensus target price of $34.00, indicating a potential upside of 440.54%. Aurinia Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 35.93%. Given Septerna's higher possible upside, analysts clearly believe Septerna is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySepterna beats Aurinia Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Remove Ads Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.30M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E RatioN/A7.2023.1319.03Price / Sales284.70226.01383.8993.17Price / CashN/A65.6738.1634.64Price / BookN/A6.476.944.33Net IncomeN/A$141.90M$3.20B$247.06M7 Day Performance6.25%-3.20%-2.32%-0.37%1 Month Performance-2.78%-5.64%2.84%-3.85%1 Year PerformanceN/A-7.47%10.75%1.27% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna2.3883 of 5 stars$6.29+2.4%$34.00+440.5%N/A$279.30M$981,000.000.00N/AEarnings ReportUpcoming EarningsNews CoveragePositive NewsAUPHAurinia Pharmaceuticals2.9846 of 5 stars$8.40+2.9%$11.50+36.9%+69.2%$1.12B$235.13M-56.00300Analyst UpgradePositive NewsADPTAdaptive Biotechnologies3.3801 of 5 stars$7.54+3.6%$9.10+20.7%+184.4%$1.12B$178.96M-6.92790SYRESpyre Therapeutics2.0271 of 5 stars$18.54+2.8%$54.83+195.8%-52.2%$1.12B$890,000.00-2.48100News CoverageSNDXSyndax Pharmaceuticals3.5468 of 5 stars$13.04+0.7%$36.00+176.1%-41.2%$1.11B$23.68M-3.59110Positive NewsSPRYARS Pharmaceuticals3.3282 of 5 stars$11.44-3.6%$31.00+171.0%+26.8%$1.11B$2.57M-22.4390Analyst RevisionNRIXNurix Therapeutics2.0442 of 5 stars$13.93+2.5%$30.88+121.7%-13.7%$1.06B$54.55M-4.82300ELVNEnliven Therapeutics2.8728 of 5 stars$21.04+1.4%$38.25+81.8%+15.5%$1.03BN/A-11.0750News CoverageNTLAIntellia Therapeutics4.4793 of 5 stars$9.58+4.8%$37.56+292.0%-68.9%$991.69M$57.88M-1.76600Analyst RevisionBGMQilian International Holding GroupN/A$10.03+4.5%N/AN/A$975.14M$25.10M0.00298Positive NewsGap UpRCUSArcus Biosciences2.507 of 5 stars$9.15-2.0%$30.25+230.5%-53.5%$962.43M$258M-2.91500 Remove Ads Related Companies and Tools Related Companies AUPH Competitors ADPT Competitors SYRE Competitors SNDX Competitors SPRY Competitors NRIX Competitors ELVN Competitors NTLA Competitors BGM Competitors RCUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SEPN Stock Free SEPN Stock Alerts